Diffuse large B-cell lymphoma (DLBCL), NOS, GCB subtype, primary central nervous system lymphoma-01

In December 2019, Mr. Wang, a teacher from Northeast China, began experiencing headaches. On December 19th, 2019, diagnostic tests revealed the following: PET-CT showed a density shadow with significantly increased FDG metabolism in the left frontal lobe and corpus callosum knee area (approximately 3.4 * 1.9 cm, SUVmax=34.4). Biopsy and immunohistochemistry confirmed diffuse large B-cell lymphoma (DLBCL, NOS, GCB subtype), with an immunophenotype indicating Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(minor+). Cerebrospinal fluid analysis revealed 6% immature lymphoid cells with morphological variability. The diagnosis was primary central nervous system lymphoma (DLBCL, GCB subtype).

After researching treatment options online, Mr. Wang learned about Lu Dao Pei Hospital's immunotherapy capabilities and promptly sought their expertise. Following thorough physical examinations and meticulous analysis by the hospital's expert team, it was decided that Mr. Wang would participate in a clinical trial for CART therapy, specifically using CD19 CART cells. He received autologous CD19 CAR-T cell infusion on April 24, 2023. By July 30, 2023, he was assessed to have achieved complete remission (CR) and has since returned to normal life.